What changed today in Aesthetics & Longevity: 6 new studies, 4 trial updates, 1 FDA announcement
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
The signal
NPHLA tracked 11 new official records on this desk today: 4 trial updates, 6 new studies, 1 FDA announcement.
Why this matters
New clearances, safety communications and research in aesthetic and regenerative medicine affect what practices offer, how they describe it and what patients are told.
What changed
- New trial registered: AnteAGE Biosomes With Radiofrequency Microneedling for Facial Skin Rejuvenation[1]
- New trial registered: AnteAGE Exosomes and PEARL Multiplier With Microneedling for Facial Skin Quality[2]
- New trial registered: Evidence-Based Integrated Protocol to Maximize Hair Follicle Survival in Follicular Unit Extraction (FUE)[3]
- New research in Drug delivery: “Numerical simulation of PDRN iontophoresis: comparison with passive diffusion and key parameter analysis”.[4]
- New research in Materials today. Bio: “Skin organoid-derived exosomes in a hydrogel system potentiate skin wound healing”.[5]
- New research in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie: “Preparation of oxygen-filled adipose-derived stem cells exosome-nanobubbles gel for ultrasound-assisted full-thickness wound healing in rats”.[6]
- New research in Advanced healthcare materials: “PRP-Integrated Conductive Hydrogels With Dynamic Crosslinking for Accelerated Wound Healing and Physiological Monitoring”.[7]
- New research in Pakistan journal of pharmaceutical sciences: “TGα2β-modified adipose-derived stem cell exosomes regulate collagen synthesis in fibroblasts and enhance chronic ulcerative wound repair through the ILK/AKT signaling…”.[8]
- Results posted on ClinicalTrials.gov: A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines[9]
- FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme[10]
- Plus 1 more official record today — browse the Aesthetics & Longevity desk feed for the full list.
- Also reported by Dermatology Times: “Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts”.[11]
- Also reported by Dermatology Times: “Alopecia Areata Awareness Month: 2026 in Review”.[12]
- Also reported by American Med Spa Association: “ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association”.[13]
Who this affects
- Med spas
- Medical directors
- Prescribers
- Practice owners & operators
- Pharmacies
Jurisdictions: Florida.
What to watch next
No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.
NPHLA takeaway
These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.
Source file
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.
Update timeline
- First published.
- Added 5 new official records.

